BiotechTube
Intellihep

Intellihep

London, United Kingdom· Est.
intellihep.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

IntelliHep is a private, pre-clinical stage biotech exploiting a proprietary platform to engineer novel heparin-based compounds. Its core focus is on in-house development of lead candidates for Alzheimer's disease and cancer, with broader potential applications in inflammation, angiogenesis, and regenerative medicine. Founded in 2019 and based in London, the company is currently pre-revenue and built on a team with deep expertise in heparin glycobiology and chemistry.

NeurodegenerationOncologyInflammationRegenerative Medicine

Technology Platform

Proprietary platform for generating novel heparin-based chemical entities through expertise in heparin glycobiology, chemistry, and protein/carbohydrate interaction screening.

Opportunities

The potential to create first-in-class therapeutics in large, underserved markets like Alzheimer's and cancer by unlocking non-anticoagulant properties of heparin.
The platform technology also offers opportunities for lucrative research collaborations and partnerships across multiple disease areas.

Risk Factors

High scientific risk associated with novel biologic mechanisms and the challenge of separating therapeutic effects from anticoagulant activity.
Significant financial risk as a pre-revenue company requiring substantial capital to advance pre-clinical programs into costly clinical trials.

Competitive Landscape

Competition includes other biotechs and academic institutions exploring glycosaminoglycan-based therapies, as well as large pharma companies with broad neurodegeneration and oncology pipelines. IntelliHep's differentiation lies in its specialized heparin-focused platform and expertise.

More companies in United Kingdom →